<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370686">
  <stage>Registered</stage>
  <submitdate>12/05/2016</submitdate>
  <approvaldate>29/06/2016</approvaldate>
  <actrnumber>ACTRN12616000854437</actrnumber>
  <trial_identification>
    <studytitle>Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?</studytitle>
    <scientifictitle>A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pancreatic ductal adenocarcinoma</healthcondition>
    <healthcondition>pancreaticoduodenectomy</healthcondition>
    <healthcondition>Lymphadenectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pancreaticoduodenectomy for Pancreatic ductal adenocarcinoma with standard or extended lymphadenectomy undergoing by the surgeons from Ruijin Hospital 
standard lymphadenectomy includes standard lymphadenectomy and No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes stations
extended lymphadenectomy includes No8p 12a 12p 14c 14d 16 lymph nodes stations and those in standard lymphadenectomy( No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b)
The details of all lymph nodes stations are described as below:
No. 5, Suprapyloric lymph nodes; No. 6, infrapyloric lymph nodes; No. 8a, lymph nodes in the anterosuperior group along the common hepatic artery; No. 8p, lymph nodes in the posterior group along the common hepatic artery; No. 12a, lymph nodes along the hepatic artery; No. 12p, lymph nodes along the portal vein; No. 12b, lymph nodes along the bile duct; No. 12c (located next to 12b), lymph nodes around the cystic duct; No. 13a, lymph nodes on the posterior aspect of the superior portion of the head of the pancreas; No. 13b, lymph nodes on the posterior aspect of the inferior portion of the head of the pancreas; No. 14, lymph nodes along the superior mesenteric artery (a &amp; b. right lateral side, c &amp; d. left lateral side ); No. 16, lymph nodes around the abdominal aorta;.No. 17a, lymph nodes on the anterior surface of the superior portion of the head of the pancreas; No. 17b, lymph nodes on the anterior surface of the inferior portion of the head of the pancreas

</interventions>
    <comparator>Standard resection/ extended resection
standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes stations
extended lymphadenectomy includes standard lymphadenectomy and No8p 12a 12p 14c 14d 16 lymph nodes stations.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All-cause mortality/ overall survial
Medical records, the follow-ups
</outcome>
      <timepoint>1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months after operation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Disease free survival (DFS)
test: blood test for tumor marker (includes:CA199, CA125, CEA, AFP, etc); biopsy (evidence of metastasis or recurrence), etc.
medical examination: scanner (CT), PET-CT; etc.</outcome>
      <timepoint>1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months after operation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of post-operative complications
(includes pancreatic fistula, biliary fistula, abdominal infection, hemorrhage, etc)
test: blood routine, drain fluid amylase, blood culture, scanner(CT), etc.</outcome>
      <timepoint>Duration of hospital stay</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Pathologic diagnosis of pancreatic ductal adenocarcinoma
2. Signed the informed consents</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pathologic diagnosis of other pancreatic cancers
2.pre-operative anti-cancer treatment 
3. recurrence patients
4.patients with contraindication(hepatic/ respiratory/  renal dysfunction, etc )
5.pre operative exam: Total bilirubine  &gt; 250micromol/L
6. AJCC stage IV
7.operation non radical</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>1/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <currentsamplesize>89</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Shanghai Ruijin Pancreatic Disease Center</primarysponsorname>
    <primarysponsoraddress>No 197 ruijin er road shanghai china 200025</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Shanghai hospital development center</fundingname>
      <fundingaddress>No.2 Kangding Road Shanghai China, 200041</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Baiyong SHEN</sponsorname>
      <sponsoraddress>No 197 ruijin er road, Shanghai Ruijin Pancreatic Disease Center, Shanghai Ruijin Hospital, shanghai china 200025</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Weishen WANG</sponsorname>
      <sponsoraddress>No 197 ruijin er road, Shanghai Ruijin Pancreatic Disease Center, Shanghai Ruijin Hospital, shanghai china 200025</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Shanghai Zhongshan Hospital</othercollaboratorname>
      <othercollaboratoraddress>No.180 Fenglin Road Shanghai, 200032</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Shanghai Xinhua Hospital</othercollaboratorname>
      <othercollaboratoraddress>No. 1665 Kongjiang Rd, Shanghai, China, 200093</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare outcomes of patients undergoing standard or
extended lymphadenectomy in pancreaticoduodenectomy for pancreatic ductal adenocarcinoma</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ruijin hospital ethics committee confidential agreement</ethicname>
      <ethicaddress>No. 197 Ruijin Er Road Shanghai, P.R china, 200025</ethicaddress>
      <ethicapprovaldate>1/03/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>19/02/2016</ethicsubmitdate>
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Weishen WANG</name>
      <address>No. 197 Ruijin Er Road Shanghai, Shanghai Ruijin Pancreatic Disease Center, Shanghai Ruijin Hospital, Shanghai, P.R China, 200025</address>
      <phone>+86 21 64370045*362174</phone>
      <fax />
      <email>peanutswey@hotmail.com</email>
      <country>China</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yuchen Yang</name>
      <address>No. 197 Ruijin Er Road Shanghai, Shanghai Ruijin Pancreatic Disease Center, Shanghai Ruijin Hospital, Shanghai, P.R China, 200025</address>
      <phone>+86 13901855633</phone>
      <fax />
      <email>89371481@qq.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Baiyong SHEN</name>
      <address>No. 197 Ruijin Er Road Shanghai, Shanghai Ruijin Pancreatic Disease Center, Shanghai Ruijin Hospital, Shanghai, P.R China, 200025</address>
      <phone>+86 21 6437 0045*671006</phone>
      <fax />
      <email>shenby@shsmu.edu.cn</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>